Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

56 patients with medial compartmental osteoarthritis and genu varum were randomized to undergo a high tibial osteotomy with or without an intra-articular injection of cultured autologous bone marrow-derived mesenchymal stem cells (MSC), administered 3 weeks post-treatment. The purpose of this study was to evaluate the clinical outcomes and MRI results of both the cell-recipient and control groups to determine whether bone marrow-derived MSC injections are safe and effective. Results after 2 years indicated that the cell-recipient group had significantly improved clinical outcomes (Tegner, Lysholm and International Knee Documentation Committee scores) and MRI results (cartilage coverage of their lesions and integration of regenerated cartilage) compared to the control group. There were no serious adverse events reported in either group.